Oncolytics Biotech Inc（ONCY）财务数据ONCYOncolytics Biotech Inc

In the context of the broader market, ONCY competes directly with industry leaders such as ELOX and INKT. With a market capitalization of $57.34M, it holds a leading position in the sector. When comparing efficiency, ONCY's gross margin of N/A stands against ELOX's N/A and INKT's N/A. Such benchmarking helps identify whether Oncolytics Biotech Inc is trading at a premium or discount relative to its financial performance.

Oncolytics Biotech has reported significant losses, with net income for Q2 2026 at -13,073,616.56 USD and a forward P/E ratio of 45.45, indicating high valuation expectations despite ongoing negative earnings.